Oncology Data Advisor™ · Updates in Myelodysplastic Syndromes: Improving Patient Outcomes Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid malignancies that derive from abnormal multipotent progenitor cells and are characterized by bone marrow failure and peripheral blood cytopenias (NCCN, 2021; Garcia-Manero et al, 2021). Survival in MDS ranges from a median of 8.8 years in the lowest-risk patients to as little as 0.8 years in the highest-risk pat...
For older patients with higher-risk myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML) with 20% to 30% marrow blasts, treatment options are limited. In the PANTHER study, the results of which were recently presented at the American Society of Hematology (ASH) 63rd Annual Meeting & Exposition in Atlanta, Georgia, a team of researchers led by Dr. Mikkael A. Sekeres, Professor of Medicine and Chief of the Division of Hematology at the Univer...
In honor of Rare Disease Day on February 28, Oncology Data Advisor spoke with Amy DeZern, MD, MHS, Director of the Bone Marrow Failure and Myelodysplastic Syndromes (MDS) Program at Johns Hopkins Medicine and member of the Aplastic Anemia and MDS International Foundation (AAMDSIF) medical advisory board. In this interview, Dr. DeZern explains the challenges of treating such a rare disease and shares some of recent promising updates in novel treatments for patients with MDS.
In honor of Rare Disease Day on February 28, Oncology Data Advisor spoke with Amy DeZern, MD, MHS, Director of the Bone Marrow Failure and Myelodysplastic Syndromes (MDS) Program at Johns Hopkins Medicine and member of the Aplastic Anemia and MDS International Foundation (AAMDSIF) medical advisory board. In this interview, Dr. DeZern explains the challenges of treating such a rare disease and shares some of recent promising updates in novel treatments for patients with MDS.
This interview has been conducted in partnership with AAMDSIF, the world's leading nonprofit health organization dedicated to supporting patients and families living with aplastic anemia, MDS, paroxysmal nocturnal hemoglobinuria, and related bone marrow failure diseases. The Foundation provides answers, support, and hope to thousands of patients and their families around the world.
A complex group of heterogenous hematopoietic disorders, myelodysplastic syndromes (MDS) often go unrecognized and undiagnosed. Accurate diagnosis and risk assessment for this condition require a myriad of tests and an in-depth evaluation of symptoms. In this excerpt from their continuing medical education (CME)/nursing continuing professional development (NCPD) virtual tumor board entitled Diagnosis and Management of Myelodysplastic Syndromes, Dr. David Steensma, Dr. Reza Nejati, and Ms. Irene ...